Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis.
Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established. In this study, an observational, retrospective and multi-center analysis was performed to explore the decitabine schedule f...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3991661?pdf=render |
| _version_ | 1819104472357404672 |
|---|---|
| author | Xiao Li Qiang Song Yu Chen Chunkang Chang Dong Wu Lingyun Wu Jiying Su Xi Zhang Liyu Zhou Luxi Song Zheng Zhang Feng Xu Ming Hou |
| author_facet | Xiao Li Qiang Song Yu Chen Chunkang Chang Dong Wu Lingyun Wu Jiying Su Xi Zhang Liyu Zhou Luxi Song Zheng Zhang Feng Xu Ming Hou |
| author_sort | Xiao Li |
| collection | DOAJ |
| description | Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established. In this study, an observational, retrospective and multi-center analysis was performed to explore the decitabine schedule for the treatment of MDS. A total of 79 patients received reduced dosage decitabine treatment (15 mg/M2/day intravenously for five consecutive days every four weeks). Fifty-three out of the 79 patients were defined as intermediate-2/high risk by international prognostic scoring system (IPSS) risk category. 67.1% of MDS patients achieved treatment response including complete response (CR) (n = 23), Partial response (n = 1), marrow CR (mCR) with hematological improvement (HI) (n = 11), mCR without HI (n = 11) and HI alone (n = 7) with a median of 4 courses (range 1-11). The median overall survival (OS) was 18.0 months. The median OS was 22.0, 17.0 and 12.0 months in the patients with CR, those with other response, and those without response, respectively. In addition, this regimen contributed to zero therapy-related death and punctual course delivery, although III or IV grade of cytopenia was frequently observed. In conclusion, the 15 mg/M2/d×5 day decitabine regimen was effective and safe for Chinese MDS patients with IPSS score of 0.5 or higher. |
| first_indexed | 2024-12-22T02:06:54Z |
| format | Article |
| id | doaj.art-9cd96d96742f4317aced3e40cf9da594 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T02:06:54Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-9cd96d96742f4317aced3e40cf9da5942022-12-21T18:42:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0194e9547310.1371/journal.pone.0095473Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis.Xiao LiQiang SongYu ChenChunkang ChangDong WuLingyun WuJiying SuXi ZhangLiyu ZhouLuxi SongZheng ZhangFeng XuMing HouDecitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established. In this study, an observational, retrospective and multi-center analysis was performed to explore the decitabine schedule for the treatment of MDS. A total of 79 patients received reduced dosage decitabine treatment (15 mg/M2/day intravenously for five consecutive days every four weeks). Fifty-three out of the 79 patients were defined as intermediate-2/high risk by international prognostic scoring system (IPSS) risk category. 67.1% of MDS patients achieved treatment response including complete response (CR) (n = 23), Partial response (n = 1), marrow CR (mCR) with hematological improvement (HI) (n = 11), mCR without HI (n = 11) and HI alone (n = 7) with a median of 4 courses (range 1-11). The median overall survival (OS) was 18.0 months. The median OS was 22.0, 17.0 and 12.0 months in the patients with CR, those with other response, and those without response, respectively. In addition, this regimen contributed to zero therapy-related death and punctual course delivery, although III or IV grade of cytopenia was frequently observed. In conclusion, the 15 mg/M2/d×5 day decitabine regimen was effective and safe for Chinese MDS patients with IPSS score of 0.5 or higher.http://europepmc.org/articles/PMC3991661?pdf=render |
| spellingShingle | Xiao Li Qiang Song Yu Chen Chunkang Chang Dong Wu Lingyun Wu Jiying Su Xi Zhang Liyu Zhou Luxi Song Zheng Zhang Feng Xu Ming Hou Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. PLoS ONE |
| title | Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. |
| title_full | Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. |
| title_fullStr | Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. |
| title_full_unstemmed | Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. |
| title_short | Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. |
| title_sort | decitabine of reduced dosage in chinese patients with myelodysplastic syndrome a retrospective analysis |
| url | http://europepmc.org/articles/PMC3991661?pdf=render |
| work_keys_str_mv | AT xiaoli decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT qiangsong decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT yuchen decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT chunkangchang decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT dongwu decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT lingyunwu decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT jiyingsu decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT xizhang decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT liyuzhou decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT luxisong decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT zhengzhang decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT fengxu decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis AT minghou decitabineofreduceddosageinchinesepatientswithmyelodysplasticsyndromearetrospectiveanalysis |